RBM47 is a Novel Immunotherapeutic Target and Prognostic Biomarker in Gliomas

Overview

Journal Sci Rep

Specialty Science

Date 2025 Jan 5

PMID 39757245

Authors

Wei Wei

Yongfu Cao

Xin Lu

Long Wang

Jianbin Li

Guojun Deng

Donghai Li

Limin Xiao

Affiliations

Soon will be listed here.

Abstract

The role of RBM47, an RNA-binding protein, in shaping the immune landscape of gliomas and tumor immune responses is yet to be fully studied. Therefore, a comprehensive investigation into the immunomodulatory roles of RBM47 in gliomas was conducted, leveraging gene expression data from multi-omic datasets. The prognosis of patients with gliomas considering RBM47 was elucidated using bioinformatics methods and clinical data, with results validated using immunohistochemistry and immunofluorescence analyses. The expression of RBM47 in gliomas was higher than that in normal tissues and was positively correlated with the World Health Organization tumor grade. Increased RBM47 expression is associated with poor prognosis in patients with glioma, serving as an independent predictor of overall survival. The nomogram combining RBM47 expression levels with clinical prognostic factors demonstrated strong predictive accuracy, achieving a C-index of up to 0.863 in both TCGA training and CGGA validation groups. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Variation Analysis indicated that RBM47 is closely related to immunity and inflammation. Single-cell sequencing and immunofluorescence assays confirmed the enrichment of RBM47 in CD163 + macrophages. Therefore, RBM47 plays a vital role in the immune microenvironment of gliomas and may be a potential immunotherapy target.

References

Xing Y, Zhu T . RNA-Binding Motif Protein RBM47 Promotes Invasiveness of Glioblastoma Through Activation of Epithelial-to-Mesenchymal Transition Program. Genet Test Mol Biomarkers. 2023; 27(12):384-392. DOI: 10.1089/gtmb.2023.0368. View

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

Liu S, Zhang C, Maimela N, Yang L, Zhang Z, Ping Y . Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma. Oncoimmunology. 2019; 8(7):1601478. PMC: 6527268. DOI: 10.1080/2162402X.2019.1601478. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Zheng Z, Chen X, Cai X, Lin H, Xu J, Cheng X . RNA-binding protein MEX3D promotes cervical carcinoma tumorigenesis by destabilizing TSC22D1 mRNA. Cell Death Discov. 2022; 8(1):250. PMC: 9072549. DOI: 10.1038/s41420-022-01049-7. View

Wurth L, Papasaikas P, Olmeda D, Bley N, Calvo G, Guerrero S . UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis. Cancer Cell. 2016; 30(5):694-707. DOI: 10.1016/j.ccell.2016.10.004. View

Bunse L, Bunse T, Kramer C, Chih Y, Platten M . Clinical and Translational Advances in Glioma Immunotherapy. Neurotherapeutics. 2022; 19(6):1799-1817. PMC: 9723056. DOI: 10.1007/s13311-022-01313-9. View

Wei W, Hong T . Analysis of KLRB1-Mediated Immunosuppressive Regulation in Adamantinomatous Craniopharyngioma. J Neurol Surg A Cent Eur Neurosurg. 2024; . DOI: 10.1055/a-2312-9813. View

Bai J, Zhang X, Meng W, Xu H, Liu Y, Zhong Y . Dioscin decreases M2 polarization via inhibiting a positive feedback loop between RBM47 and NF-κB in glioma. Phytomedicine. 2024; 128:155417. DOI: 10.1016/j.phymed.2024.155417. View

10.

Goswami S, Walle T, Cornish A, Basu S, Anandhan S, Fernandez I . Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2019; 26(1):39-46. PMC: 7182038. DOI: 10.1038/s41591-019-0694-x. View

11.

Mathewson N, Ashenberg O, Tirosh I, Gritsch S, Perez E, Marx S . Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021; 184(5):1281-1298.e26. PMC: 7935772. DOI: 10.1016/j.cell.2021.01.022. View

12.

Hambardzumyan D, Gutmann D, Kettenmann H . The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2015; 19(1):20-7. PMC: 4876023. DOI: 10.1038/nn.4185. View

13.

Liu S, Sun Q, Ren X . Novel strategies for cancer immunotherapy: counter-immunoediting therapy. J Hematol Oncol. 2023; 16(1):38. PMC: 10099030. DOI: 10.1186/s13045-023-01430-8. View

14.

Qin Y, Sun W, Wang Z, Dong W, He L, Zhang T . RBM47/SNHG5/FOXO3 axis activates autophagy and inhibits cell proliferation in papillary thyroid carcinoma. Cell Death Dis. 2022; 13(3):270. PMC: 8956740. DOI: 10.1038/s41419-022-04728-6. View

15.

van den Bent M, Geurts M, French P, Smits M, Capper D, Bromberg J . Primary brain tumours in adults. Lancet. 2023; 402(10412):1564-1579. DOI: 10.1016/S0140-6736(23)01054-1. View

16.

Yu K, Hu Y, Wu F, Guo Q, Qian Z, Hu W . Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. Natl Sci Rev. 2021; 7(8):1306-1318. PMC: 8289159. DOI: 10.1093/nsr/nwaa099. View

17.

Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M . Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci. 2021; 113(2):756-769. PMC: 8819299. DOI: 10.1111/cas.15236. View

18.

Zhao L, Cheng S, Fan L, Zhang B, Xu S . TIM-3: An update on immunotherapy. Int Immunopharmacol. 2021; 99:107933. DOI: 10.1016/j.intimp.2021.107933. View

19.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

20.

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View